Search

Recent epidemiological studies highlighted a possible link between PsO and demyelinating disorders such as MS.[2] Herein, we reported the case of a 40-year-old female who suffered from PsO and MS successfully treated with a combination therapy of secukinumab and fingolimod. Keywords: fingolimod; multiple sclerosis; psoriasis; real-life experience; secukinumab EN fingolimod multiple sclerosis psoriasis real-life experience secukinumab e100 e102 3 02/17/23 20230201 NES 230201 Dear Editor, Psoriasis (PsO) is a chronic inflammatory disease characterized by erythemato-desquamative plaques with systemic involvement (psoriatic arthritis, metabolic syndrome, cardiovascular disorders, Crohn's disease, and depression).[1] Multiple sclerosis (MS) is an auto-immune neurological disease characterized by inflammation, demyelination, gliosis, and neuronal loss. [Extracted from the article]

Keywords: alopecia areata; COVID-19; herpes zoster; vaccine EN alopecia areata COVID-19 herpes zoster vaccine 36 38 3 01/23/23 20230101 NES 230101 The Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic spread over the world in 2019. Herpes zoster and alopecia areata following mRNA BNT162b2 COVID-19 vaccine: Controversial immune effects 2022; 35 (5): e15411. doi: 10.1111/dth.15411 7 May Lee M, Bertolani M, Pierobon E, Lotti T, Feliciani C, Satolli F. Alopecia areata following COVID-19 vaccination: vaccine-induced autoimmunity?. [Extracted from the article]

The author wrote some comments on our recently published article entitled 'Could wide tattoo delay the early diagnosis of cutaneous melanoma? '.[1] The patient described in our paper, skin photo-type III according to Fitzpatrick, had a negative anamnesis for melanoma and a negative family history as well. We agree with the author when he states that the upper back is an area of difficult self-control regardless of the tattoo particularly in unmarried patients,[2] but in our case, the patient's marital status could not affect it since the patient is married. [Extracted from the article]

MM prognosis is related to Breslow index (a measure of deepness of melanoma) and sentinel lymph node. Dear Editor, Herein, we report a case of a 32-year-old woman, Caucasian, phototype IV, with an insurgence of a single pigmented lesion developed on a wide tattoo in the back. [Extracted from the article]

We retrospectively investigated all the surgical excisions with a histopathological diagnosis of melanoma performed in our department from January 2018 to December 2021 in order to analyse how COVID-19 pandemic impacted on melanoma diagnosis during these years. 2022; 36: e762 - 4. https://doi.org/10.1111/jdv.18337 5 Villani A, Fabbrocini G, Scalvenzi M. The reduction in the detection of melanoma during the coronavirus disease 2019 (COVID-19) pandemic in a melanoma center of South Italy. Melanoma is the main cause of death from skin cancer.[1]Its stage at the moment of the diagnosis, particularly primary tumour thickness, is the main prognostic factor, leading to the need for an early diagnosis and treatment.[1] Restrictive measures adopted during COVID-19 pandemic in order to avoid infection spreading led to a reduction in the number of accesses in dermatologic clinics.[[2]] We read with great interest the article recently written by Balakirski et al.[4] evaluating the long-term effect of COVID-19 pandemic on the detection and dermatosurgical treatment of melanoma, and we also want to report the experience of our third-level centre for 'Melanoma Diagnosis and Prevention. [Extracted from the article]

Pityriasis rosea Gibert type rash in an asymptomatic patient that tested positive for COVID-19. Dear Editor, We read with great interest the article by Veraldi et al. on the relationship between pityriasis rosea (PR) and COVID-19 infection.1 In response to the above-mentioned article we would like to share our experience on a case of PR diagnosed after COVID-19 infection with atypical clinical presentation, and low responsiveness to conventional treatments. Can COVID-19 cause atypical forms of pityriasis rosea refractory to conventional therapies?. [Extracted from the article]

Introduction: Vitiligo is an acquired skin disorder clinically characterized by hypopigmentated macules and patches. Psoriasis is a chronic-inflammatory-skin-condition characterized by erythematous-plaques covered with scales particularly over the extensor-surfaces, scalp, and lumbosacral region. Recent major-researches-advancements have significantly expanded our understanding of psoriasis-pathophysiology, resulting in the development of highly effective targeted-therapies, such as anti TNFα, IL-12/23-inhibitors, IL-17-inhibitors, or IL-23-inhibitors. Particularly, ixekizumab, a humanized-monoclonal immunoglobulin-G 4 antibody, specifically binding IL-17A, demonstrated strong efficacy in threating recalcitrant psoriasis. Nevertheless, paradoxical reactions due to IL-17 inhibitors have been described., Case Report: Herein, we report the case of a 53-year-old Caucasian man who obtained complete skin clearance of psoriasis plaques after 16 weeks of ixekizumab treatment together with the appearance of vitiligo patches localized on the facial area. He had never suffered of vitiligo and his family history excluded vitiligo diagnosis. We also could exclude post inflammatory psoriasis hypopigmentation because of absence of facial involvement at baseline. Our experience suggests that vitiligo might be considered a rare adverse effects of anti-IL-17 therapy., (© 2021 The Authors. Dermatologic Therapy published by Wiley Periodicals LLC.)